Bone Abstracts

Loss of skeletal muscle mass and function in humans is associated with significant morbidity and mortality. The role of myostatin as a key negative regulator of skeletal muscle mass and function has supported the concept that inactivation of myostatin could be a useful approach for treating muscle wasting diseases. The human monoclonal antibody REGN1033 is a specific and potent myostatin antagonist. Treatment of mice with REGN1033 increased muscle fiber size, muscle mass, and ...